ANI Pharmaceuticals, Inc. (ANIP) Upgraded at ValuEngine
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Saturday.
Several other equities analysts also recently weighed in on the company. Canaccord Genuity reissued a “buy” rating on shares of ANI Pharmaceuticals in a research report on Thursday. BidaskClub raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $67.33.
ANI Pharmaceuticals (ANIP) traded up $4.43 during trading on Friday, reaching $61.97. The company’s stock had a trading volume of 350,499 shares, compared to its average volume of 114,474. The company has a quick ratio of 2.49, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $721.52 million, a P/E ratio of 17.78 and a beta of 2.84. ANI Pharmaceuticals has a one year low of $42.23 and a one year high of $65.81.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.12. The company had revenue of $48.16 million during the quarter, compared to the consensus estimate of $48.12 million. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. ANI Pharmaceuticals’s revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.09 earnings per share. research analysts anticipate that ANI Pharmaceuticals will post 3.52 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its position in shares of ANI Pharmaceuticals by 106.5% in the third quarter. BNP Paribas Arbitrage SA now owns 4,443 shares of the specialty pharmaceutical company’s stock valued at $233,000 after purchasing an additional 2,291 shares during the period. Principal Financial Group Inc. grew its position in shares of ANI Pharmaceuticals by 10.6% in the third quarter. Principal Financial Group Inc. now owns 67,579 shares of the specialty pharmaceutical company’s stock valued at $3,547,000 after purchasing an additional 6,501 shares during the period. Prudential Financial Inc. grew its position in shares of ANI Pharmaceuticals by 9.2% in the third quarter. Prudential Financial Inc. now owns 15,230 shares of the specialty pharmaceutical company’s stock valued at $799,000 after purchasing an additional 1,280 shares during the period. Chicago Equity Partners LLC grew its position in shares of ANI Pharmaceuticals by 13.8% in the third quarter. Chicago Equity Partners LLC now owns 22,570 shares of the specialty pharmaceutical company’s stock valued at $1,185,000 after purchasing an additional 2,745 shares during the period. Finally, Dupont Capital Management Corp purchased a new stake in shares of ANI Pharmaceuticals in the third quarter valued at $450,000. 55.96% of the stock is owned by institutional investors and hedge funds.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.